

# PHARMACY TIMES

**BY IEHP PHARMACEUTICAL SERVICES DEPARTMENT**  
**February 2022**

**RETRACTION - Medi-Cal Rx Transition: Continuous Glucose Monitors (CGM)**

Dear IPA Partners,

Inland Empire Health Plan (IEHP) would like to apologize for the confusion surrounding authorization submission for Type 1 Continuous Glucose Monitors (GCM). This notice serves to clarify and also precedes the DOFR amendment that will be sent shortly now that this concern has resolved.

Please **disregard** our last communication advising Providers to submit an authorization request to either the state PBM Magellan **OR** submit to IEHP.

We will return to the process effective January 1, 2022: All authorizations for Type 1 Continuous Glucose Monitor (GCM) must be submitted directly to PBM Magellan. Submissions for Type 2, will remain the same:

Please see the updated summary of coverage below:

Member Diagnosis	Device Type	Billing
<b>Type 1 Diabetes</b>	Therapeutic CGM Monitor and Supplies	Submit to Medi-Cal Rx (Magellan)
	Non-Therapeutic CGM Monitor	Not a covered benefit
	<b>IEHP Direct:</b> Submit to Medi-Cal Rx (Magellan)	<b>IEHP Direct:</b> submit eAuth to IEHP with DME Providers indicated as servicing provider <b>IPA:</b> authorization request should be submitted to IPA
<b>Type 2 Diabetes</b>	Therapeutic CGM Monitor and Supplies	<b>IEHP Direct:</b> submit eAuth to IEHP with DME Providers indicated as servicing provider <b>IPA:</b> authorization request should be submitted to IPA
	Non-Therapeutic CGM Monitor	Not covered benefit
	Non-Therapeutic CGM Supplies	<b>IEHP Direct:</b> submit eAuth to IEHP with DME Providers indicated as servicing provider <b>IPA:</b> authorization request should be submitted to IPA

**What is the difference between a therapeutic and non-therapeutic CGM?**

DHCS states CGM devices not having FDA designation as a therapeutic CGM are considered “nontherapeutic” CGMs and are considered as an “adjunct use” to blood glucose monitor testing. Diabetic treatment decisions must still be made using a home blood glucose monitor test.

If you have any questions regarding Provider-related issues, please contact the Provider Relations Team at **(909) 890-2054** or **(866) 223-4347** or email [\*\*ProviderServices@iehp.org\*\*](mailto:ProviderServices@iehp.org).

If you have any additional questions, please feel free to contact the Pharmacy Team at **(909) 890-2049**, between 8:00 AM -5:00 PM, Monday through Friday.

As a reminder, all communications sent by IEHP can also be found on our Provider portal at: [www.iehp.org](http://www.iehp.org) > For Providers > Plan Updates > Correspondences

Visit the new Medi-Cal Rx website [www.Medi-CalRx.dhcs.ca.gov](http://www.Medi-CalRx.dhcs.ca.gov) for general information, including Frequently Asked Questions (FAQs) and the Medi-Cal Rx Pharmacy Transition Policy.

Sincerely,

IEHP Pharmaceutical Services

RETRACTION - Medi-Cal Rx Transition: Continuous Glucose Monitors (CGM) UPDATE

February 17, 2022

Page 2 of 2

10801 6<sup>th</sup> St., Suite 120, Rancho Cucamonga, CA 91730

Tel (909) 890-2049 Fax (909) 890-2058

Visit our web site at: [www.iehp.org](http://www.iehp.org)

*A Public Entity*